From 18 to 20 November 2025, the CARAMEL consortium gathered in Seville for its third plenary meeting, hosted by SASdigital and FISEVI, at the IBIS Hospital. Over three days, partners from Europe and Latin America came together to reflect on a successful first year and coordinate next steps toward the launch of the project’s digital components.

The meeting opened with a full-day training dedicated to the CARAMEL Observational Study (CARAMEL-OS), set to launch in early 2026. Clinical teams from all six pilot sites reviewed study protocols, patient enrolment processes, and data collection procedures. The session also included hands-on demonstrations of the medical devices and wearables to be used in the study, including the asApp developed by Particle, iBreve wearable, Smartnanosense skin patch, ULMA’s retinal imaging device, and REDCap data capture platform.

In the following days, partners reviewed progress across key areas: from the CARAMEL-WOMEN survey (with over 7,400 responses) and multi-source data integration, to the AI-based CVD stratification scheme and the development of the CVD prevention portal. Dedicated sessions on dissemination, ethics, and co-creation reaffirmed the project’s inclusive and collaborative approach.

With a clear roadmap and strengthened alignment across technical and clinical teams, CARAMEL is now fully focused on entering its next phase.

Want to know more about our progress and what’s coming next? Check the updated Project Brief and follow us on LinkedIn for highlights from the meeting.